Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2002247946B2 - Process for the preparation of nanosized iron oxide by biomimetic route - Google Patents
[go: Go Back, main page]

AU2002247946B2 - Process for the preparation of nanosized iron oxide by biomimetic route - Google Patents

Process for the preparation of nanosized iron oxide by biomimetic route Download PDF

Info

Publication number
AU2002247946B2
AU2002247946B2 AU2002247946A AU2002247946A AU2002247946B2 AU 2002247946 B2 AU2002247946 B2 AU 2002247946B2 AU 2002247946 A AU2002247946 A AU 2002247946A AU 2002247946 A AU2002247946 A AU 2002247946A AU 2002247946 B2 AU2002247946 B2 AU 2002247946B2
Authority
AU
Australia
Prior art keywords
iron oxide
preparation
solution
nanosized
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002247946A
Other versions
AU2002247946A1 (en
Inventor
Jui Chakraborty
Samar Das
Swapan Kumar Das
Patcha Ramachandra Rao
Venkatesh Rao
Arvind Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of AU2002247946A1 publication Critical patent/AU2002247946A1/en
Application granted granted Critical
Publication of AU2002247946B2 publication Critical patent/AU2002247946B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01FMAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01FMAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0063Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use in a non-magnetic matrix, e.g. granular solids

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Power Engineering (AREA)
  • Radiology & Medical Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Iron (AREA)

Description

WO 03/081612 PCT/IN02/00070 PROCESS FOR THE PREPARATION OF NANOSOZED IRON OXIDE BY BIOMIMETIC ROUTE Field of the invention The present invention relates to a process for the preparation ofnanosized iron oxide by biomimetic route. The present invention particularly relates to a biomimetic process for preparation of nanosized magnetite particles used for the enhancement of magnetic resonance imaging contrast. The nanosized magnetite, a form of iron oxide, is biodegradable, nontoxic and has size in the range of 4-20 nanometer. The particles, being super-paramagnetic in nature and exhibiting a narrow size distribution, arte useful generally in the fields of medical treatment and specifically of Magnetic Resonance Imaging.
Background of the invention Magnetic resonance imaging (MRI) is widely used for diagnostic imaging of the soft tissues and has been proven to be better to computed tomography for the detection of lever metastases. The screening and follow up of any kind of metastasis using contrast-enhanced MRI is an interesting tool for oncologists because ultrasound (US) is operator dependent and not always reproducible. Therefore, various contrast agents for an improved MR imaging have been developed by the pharmaceutical companies to serve the purpose.
Several metal chelates comprising of a highly magnetic cation Gd such as Gd- DTPA (Diethylene Triamine Pentaacetic Acid) are available for ready clinical use. These agents have been applied in enhancing the image contrast either as coating material in a therapeutic device or as directed agents for a specific organ. The only commercially available iron oxide for use in MRI contrast is ferumoxide, which has a supraparamagnetic crystalline core (nanosized magnetite) surrounded by dextra-coating. Being produced by conventional chemical method these magnetite particles suffer the limitations of the chemical synthesis route such as poor control over size and morphology. Thus, the supraparamagnetic behaviour of the particles ultimately deteriorates and makes them unsuitable for applications.
In a conventional method of production of nanosized magnetite particles developed by David and Welch. David and A.J.E. Welch, Trans. Faraday Soc. 52 (1956) 1642) ferrous sulphate solution is heated to 90'C and a solution of potassium hydroxide and potassium nitrate added drop-wise over a few minutes. The suspension was heated for minutes with continuous stirring followed by cooling, washing and drying leading to the formation of black precipitate of magnetite powder. It is mandatory to carry out the entire under an atmosphere of nitrogen.
In another known process by Schikorr G. Schikorr, Z. Electrochem 35 (1929) alkaline hydrolysis of ferrous sulphate solution is carried out to yield ferrous hydroxide followed by it's further oxidation at 100°C leading to the formation of magnetite powder along with evolution of hydrogen gas.
In another known process, reaction of ferrous/ferric solution under alkaline condition at 80°C under nitrogen atmosphere leads to the formation of magnetite particles (Regazzoni Urrutia Blesa M.A. and Maroto A.J.G. Inorg. Nucl.
Chem, 43 (1981) 1489).
In hitherto known processes the magnetite particles produced have poor crystallinity, a wide range of size distribution, random variation in morphology and magnetically induced agglomeration. The above limitations reduce the applicability of the magnetite particles in the field of medicine.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
Summary of the Invention In a preferred embodiment, the present invention provides a process for preparation of nanosized iron oxide by biomimetic route, which obviates the drawbacks as detailed above.
In another preferred embodiment, the present invention provides a biomimetic process for preparation of nanosized magnetic particles used for enhancement of magnetic resonance imaging contrast.
In one aspect, the present invention provides a process for preparation of nanosized iron oxide by biomimetic route which comprises: i) mixing polyvinyl alcohol of strength ranging between 0. 1-0.6% and disodium tetraborate solution of strength ranging between 01-0.6% in deionised water with continuous stirring; ii) mixing the above said reaction mixture with an iron salt solution of strength ranging between 0.01-0.02 M in deionised water under nitrogen atmosphere, at a pH in the range of 3-6 and stirring for about 20 minutes with a magnetic stirrer; iii) heating the above resultant solution at a temperature in the range of 40-60"C for a period of about 24 hours under nitrogen atmosphere to obtain an iron ion loaded cross linked polymer gel; iv) soaking the above said polymer gel for a period ranging from 2 to 4 hours into sodium hydroxide solution of strength ranging between 0.00-0.009M, at a temperature ranging between 40-50 °C; v) washing the above soaked polymer gel with de-ionized water to remove the sodium chloride salt and recovering the nanosized iron oxide particles from the soaked polymer gel.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
WO 03/081612 PCT/IN02/00070 In one embodiment of the invention, the polyvinyl alcohol and disodium tetraborate solution are taken in a volumetric ratio ranging between 9:1 to 12:1 In another embodiment of the invention, the reaction mixture obtained in step and the iron salt solution are taken in a volumetric ratio ranging from 2:1 to 5:1.
In an embodiment of the invention the iron salt solution used is a mixture of ferric chloride and ferrous chloride in de-ionized water.
Detailed description of the invention In nature, the synthesis of nano and micro sized inorganic particles is observed since the evaluation of life. The process is termed as bio-mineralization and it exhibits a high degree of control over the nucleation and growth of the synthesized particles, which perform different functions under different conditions and do not agglomerate. Our teeth, bones, shells, etc. are the products of biomineralization and nature carries out these in situ synthesis under the control of a biopolymeric matrix.
In the process of present invention in laboratory a method has been developed for in situ precipitation of nanosized magnetite particles in a pre-organized polymeric matrix made of a water-soluble polymer like polyvinyl alcohol at room temperature. The method produced magnetite particles in the size range of 5-10 nm having uniform morphology and orientation with supraparamagnetic behavior.
Under the optimum conditions of temperature, concentration, pH and a specific volumetric ratio, the underlying polymeric matrix provides a regularly arranged and uniformly distributed reaction as well as nucleation sites in the self assembled polymeric network formed as a result of gelation and cross-linking. The process involves a weak complexion (via dative bond formation) of ferrous/ferric ions (acceptor atom) with the active functional groups (donor atom) of the underlying polymer. An enhancement in the degree of saturation of ferrous/ferric ions locally at the complexion sites leads to the precipitation of nanosized magnetite particles under alkaline conditions at an optimum temperature.
Adsorption of the polymer at the surface of the precipitate limits the dimensions of particles in nanometer size range and the polymer matrix anisotropy induces an orientation during the particle growth.
By the process of the present invention, a single phase agglomeration free magnetite particles in size range of 5-10 nanometer and oriented in form of linear arrays are produced.
The novelty of the present route is the in situ synthesis of the magnetite particles in preorganized polymer matrix. The polymer matrix controls the particles shape and size and regulates the precipitation process. The inventive step of the present invention is the chelation WO 03/081612 PCT/IN02/00070 of ferrous ions by weak van der Wall bonds and hydrogen bonds present in cross-liked polymer matrix. The cross linking of the polymer provides a biopolymer like medium for mineralization which is characterized by regular arrangement of nano reactors and avoids agglomeration of the particles and induce precipitation under mild conditions of super saturation.
The following examples are given by way of illustration and should not be construed to limit the scope of the present invention.
Example 1 ml 0.5% polyvinyl alcophol was mixed with 15 ml of 0.013 M iron salt solution (prepared by dissolving ferric chloride and ferrous chloride salt in the deionized water in the ratio by weight of 3:2) in the volumetric ratio of 4:1 by continuous stirring using a magnetic stirrer. The pH of the solution was observed 3. The resulting solution was poured into a Petri dish and subjected to gel formation in an oven at 40 0 C maintaining nitrogen atmosphere for 24 hours. The thin dried light yellow film (gel) was soaked for 4 hours in 0.00625 M sodium hydroxide solution taken in a beaker and heated to 40 0 C following which color of the film changed from light yellow to black. Next, the black film was washed thoroughly by diionized water and again it was dried at 40 0 C in the same oven maintaining nitrogen atmosphere for 24 hours. Finally, the washed and dried sample was structurally characterized using X-ray diffraction, scanning electron microscopy and transmission electron microsocopy. The analysis of the results obtained confirmed the formation of single phase magnetite particles in the form of oriented and regularly arranged linear arrays having a low particle density showing agglomeration to certain extent and size in the range of 10-40nm.
Recovery of the iron oxide was close to 100%.
Example 2 60 ml of 0.5% polyvinyl alcohol solution was mixed with 6 ml of 0.5% disodium tetra borate solution in the volume ratio of 10:1 mixed by continuous stirring using a magnetic stirrer. Net, 15 ml of 0.013 M iron salt solution (prepared by dissolving ferric chloride and ferrous chloride salts in de-ionized in the ratio 3:2) was added in a volume ratio 4:1 by continuous stirring using a magnetic stirrer. The pH of the solution was observed to be 5. The resulting solution was poured into a Petri dish and was subjected to gel formation in an oven at 40°C maintaining nitrogen atmosphere. The dried film was soaked in 0.00625M sodium hydroxide take in a beaker heated to 40 0 C, for 4 hours following which, color of the film changed from light yellow to black. Next, the film was washed thoroughly with de-ionized water and dried in an oven at 60 0 C for 24 hours maintaining nitrogen atmosphere. The WO 03/081612 PCT/IN02/00070 washed and dried sample was structurally characterized by X-ray diffraction, scanning electron microscopy and transmission electron microscopy. The analysis of the results obtained linear arrays widely distributed throughout the matrix network being parallel to each other. The particle size in the case was observed to be decreased to a range of 10-20 r1n.
More number of arrays with increased particle density and almost without any agglomeration was observed in this case. The recovery rate of iron oxide was close to 100%.
Example 3 ml of 0.5% polyvinyl alcohol solution was mixed with 6 ml 0.5% disodium tetra borate solution with continuous stirring using magnetic stirrer at room temperature. The pH of the solution was observed -to be 5. To this, 15 ml of iron salt solution (prepared by dissolving ferric chloride and ferrous chloride salt in deionized water in the ratio 3:2) was added, again with continuous stirring and the resulting solution was poured into a Petri dish and kept in an oven for gel formation at 40 0 C under nitrogen atmosphere for 24 hours. Next, the dried light yellow gel was soaked for 4 hours in 0.00625 M sodium hydroxide solution taken in a beaker and heated to 40 0 C, following which color of the gel changes from light yellow to black. It was washed 4 to 5 times with de-ionized water and dried at 40 0 C in an oven under nitrogen atmosphere. The washed and dried film was structurally characterized by X-ray diffraction, scanning electron microscopy and transmission electron microscopy.
The analysis of data indicated the presence of single phase magnetite in the form of linearly oriented arrays, arranged regularly, parallel to each other widely distributed throughout the matrix with high particle density in the matrix nucleation sites. The particle size in this case ranged from 5-10 nm, had a high aspect ratio and were with no agglomeration. The recovery rate of iron oxide was close to 100%.
The main advantages of the present inventions are: 1. The invention provides a room temperature process for the preparation of nanosized magnetite particles suitable for application in magnetic resonance image contrast enhancement.
2. The invention leads to agglomeration free magnetite particles with uniform shape and size.
3. The size distribution of the particles is very narrow.
4. The produced particles being super-paramagnetic in nature can be used in other applications also involving ferro fluids.

Claims (6)

  1. 2. A process as claimed in claim 1 wherein the polyvinyl alcohol and disodium tetraborate solution are taken in a volumetric ratio ranging between 9:1 to 12:1.
  2. 3. A process as claimed in claim 1 or 2 wherein the reaction mixture obtained in step and the iron salt solution are taken in a volumetric ratio ranging from 2:1 to 5:1.
  3. 4. A process as claimed in any one of claims 1-3 wherein the iron salt solution used is a mixture of ferric chloride and ferrous chloride in de-ionized water.
  4. 5. A process as claimed in any one of claims 1-4 wherein the polymer gel is in the form of a polymer matrix and controls the size and shape of the iron oxide formation.
  5. 6. A process as claimed in claim 5 wherein the ferric and ferrous ions are chelated by weak van der Wall bonds and hydrogen bonds present in the polymer matrix.
  6. 7. A process for preparation of nanosized iron oxide by biomimetric route, substantially as hereinbefore described with reference to any one of Examples 1-3. Dated this fourteenth day of June 2007 Council of Scientific and Industrial Research Patent Attorneys for the Applicant: F B RICE CO
AU2002247946A 2002-03-26 2002-03-26 Process for the preparation of nanosized iron oxide by biomimetic route Ceased AU2002247946B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000070 WO2003081612A1 (en) 2002-03-26 2002-03-26 Process for the preparation of nanosozed iron oxide by biomimetic route

Publications (2)

Publication Number Publication Date
AU2002247946A1 AU2002247946A1 (en) 2003-10-08
AU2002247946B2 true AU2002247946B2 (en) 2007-10-04

Family

ID=28053428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002247946A Ceased AU2002247946B2 (en) 2002-03-26 2002-03-26 Process for the preparation of nanosized iron oxide by biomimetic route

Country Status (4)

Country Link
KR (1) KR100626096B1 (en)
AU (1) AU2002247946B2 (en)
GB (1) GB2403215B (en)
WO (1) WO2003081612A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070044817A (en) * 2004-06-27 2007-04-30 조마 케미칼 에이에스 Method for producing iron oxide nanoparticles
IT1397612B1 (en) * 2009-12-15 2013-01-18 Colorobbia Italia Spa MAGNETITE IN NANOPARTICELLAR FORM

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600529A2 (en) * 1992-12-02 1994-06-08 NanoSystems L.L.C. Preparation and magnetic properties of very small magnetite-dextran particles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600529A2 (en) * 1992-12-02 1994-06-08 NanoSystems L.L.C. Preparation and magnetic properties of very small magnetite-dextran particles

Also Published As

Publication number Publication date
KR20040111453A (en) 2004-12-31
KR100626096B1 (en) 2006-09-21
WO2003081612A1 (en) 2003-10-02
AU2002247946A1 (en) 2003-10-08
GB2403215B (en) 2005-10-12
GB2403215A (en) 2004-12-29
GB0421445D0 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
Daou et al. Coupling agent effect on magnetic properties of functionalized magnetite-based nanoparticles
Yuen et al. The interplay of catechol ligands with nanoparticulate iron oxides
Liu et al. Water-dispersible magnetic carbon nanotubes as T2-weighted MRI contrast agents
Vinslava et al. Molecules at the quantum–classical nanoparticle interface: giant Mn70 single-molecule magnets of∼ 4 nm diameter
JP5569837B2 (en) Method for producing surface-coated inorganic particles
US6800271B2 (en) Process for the preparation of nanosized iron oxide by biomimetic route
Chiu et al. Enhanced Raman sensitivity and magnetic separation for urolithiasis detection using phosphonic acid-terminated Fe 3 O 4 nanoclusters
Lassenberger et al. Biocompatible glyconanoparticles by grafting sophorolipid monolayers on monodispersed iron oxide nanoparticles
TW200914049A (en) One kind of nanometer-scaled magnetic hydroxyapatite particle and its manufacturing method
CN117797282B (en) Polyaspartic acid grafted dopamine and ethanolamine polymer chelated iron oxide nanoparticles and their radionuclide labeling
Pazik et al. Energy conversion and biocompatibility of surface functionalized magnetite nanoparticles with phosphonic moieties
Khosroshahi et al. Characterization and Cellular Fluorescence Microscopy of Superparamagnetic Nanoparticles Functionalized with Third Generation Nano-molecular Dendrimers: In-vitro Cytotoxicity and Uptake study. J Nanomater Mol Nanotechnol 5: 3
AU2002247946B2 (en) Process for the preparation of nanosized iron oxide by biomimetic route
Caspani et al. Anisotropic porous iron-based nanoparticles through two-step hydrothermal and hydrogen-based reduction: Enhanced magnetic performance for potential biomedical applications
AU2019203072B2 (en) A multimodal pet/mri contrast agent and a process for the synthesis thereof
CN109516503A (en) A kind of preparation method of high stability water-base nano magnetic fluid
Carron et al. Potential theranostic and multimodal iron oxide nanoparticles decorated with rhenium–bipyridine and–phenanthroline complexes
Katkova et al. Water-soluble 15-metallacrown-5 complexes: Molecular structures and properties
Dietrich et al. Electron Beam-Assisted Synthesis of Superparamagnetic Iron Oxide Nanoparticles: Reaction Kinetics and Structural–Magnetic Properties
CN102430130B (en) Medical modified glucan coated magnetic nanometer particle composite material and preparation method thereof
Li et al. Application of Gd (III) complexes for magnetic resonance imaging and the improvement of relaxivities via nanocrystallization
CN113058044B (en) Dynamic organic gadolinium nanoparticles and application thereof
Chen et al. Localized assembly-based laponite for high dual-mode activity and biocompatibility
CN112516334B (en) A kind of EDTMP modified ferric oxide nanoparticles and preparation method and application thereof
KR101136190B1 (en) Magnetic nano-particles coated by biocompatible polymer and method for manufacturing the same

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO PROCESS FOR THE PREPARATION OF NANOSIZED IRON OXIDE BY BIOMIMETIC ROUTE.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired